MacroGenics Phase 2 TAMARACK safety data shows improved tolerability at lower vobra duo doses

MACROGENICS INC

Drug interruption rate 12.6% vs 58.5% at 12 weeks in Phase 1; discontinuation 5.3% vs 14.6%.
No fatal AEs; most common TEAEs: asthenia (40.7%), nausea (27.7%), fatigue (20.3%).
ASCO abstract not accepted; plan to share updated interim safety + efficacy by May 31, 2024.
rPFS primary endpoint data expected Fall 2024; IDMC recommended study continue unchanged.
Enrolled 182 mCRPC patients across 2.0 and 2.7 mg/kg Q4W dose arms; 85.7% still on treatment.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.